X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).
Lead Product(s): NDI-5001
Therapeutic Area: Rare Diseases and Disorders Product Name: NDI-5001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: McQuade Center for Strategic Research and Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2023
Details:
NephroDI’s lead product, NDI-5033 is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output.
Lead Product(s): NDI-5033
Therapeutic Area: Genetic Disease Product Name: NDI-5033
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xontogeny, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
